“Latest Stem Cells News”

(…) Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells, that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials. The REGEN trial is designed to test the safety and effectiveness of a composition of muscle stem cells that have been gene-modified to induce a greater than usual release of the SDF-1 protein. The SDF-1 protein is a molecule in the human body that, after an injury, is naturally released by most tissues to attract stem cells. The stem cells assist with the healing process.

Unlike other tissues, the heart muscle does not release enough SDF-1 to attract the number of stem cells that would result in complete self-healing. As a result, scar tissue forms and impairs normal heart function.

Results from Bioheart’s preclinical animal studies have shown that the genetically modified MyoCell® is far more effective than MyoCell® alone in accomplishing repair and tissue regeneration. With SDF-1, there is a release of additional therapeutic proteins to assist in the tissue repair process, resulting in a more expansive and quicker repair. Once that repair or regeneration has occurred, the patient’s improved heart function permits the patient to return to a normal life style.

The first-ever dental stem cell bank in India called “Store your Cells” has now been launched. This unique bank is the venture of started by dentists at Dhruv Polyclinic, Mumbai.

The venture was formed under the guidance of Dr. Kedar Gadgil, who is a successful implant dentist practising at London (UK), Kent (UK), and Mumbai . He is the Director and lead clinician of Dhruv Polyclinic.

The King Abdulaziz Medical City in Riyadh is getting ready to open a stem cell bank harvested from the umbilical cord. The procedure will be done in laboratories and specially equipped rooms to draw the cells from umbilical cord blood and separate them using a special device.

Then they will be stored in labs for a period from 15 to 20 years after examining them and making sure they are free of contagious and genetic diseases. In addition, a team will be prepared for coordinating, marketing and research within this field.

(…) Dr. Weiner says the collaboration has resulted in 12 to 15 Phase III trials for new medications, an exploration into stem cell transplantation and a compilation of new information about importance of vitamin D. Studies show boosting vitamin D in MS patients can bring improvement in symptoms (…)

The Australian Stem Cell Centre (ASCC) through StemCore, its national facility for the provision of stem cells and advice, continues to build a world class Australian stem cell research community. For the first time in Australia, young researchers will be trained in the techniques of growing and using human induced pluripotent stem (iPS) cells in research.

iPS cells, discovered in 2006 when Japanese scientists reprogrammed ordinary skin cells into versatile stem cells, have made a significant impact on Australian research and are recognised as one of the most important developments in stem cell research in recent times. By offering the long-term prospect of personalised and disease specific cell lines being available for treating disease, testing medicines and for research purposes, they represent a new and innovative way for scientists to study and understand disease and development.